E1515000
Erythropoietin
BRP, European Pharmacopoeia (EP) Reference Standard
Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
About This Item
Produits recommandés
Famille d'API
erythropoietin
Application(s)
pharmaceutical (small molecule)
Format
neat
Description générale
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.
Application
Erythropoietin EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.
Conditionnement
The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
Autres remarques
Sales restrictions may apply.
Code de la classe de stockage
11 - Combustible Solids
Classe de danger pour l'eau (WGK)
WGK 3
Point d'éclair (°F)
Not applicable
Point d'éclair (°C)
Not applicable
Faites votre choix parmi les versions les plus récentes :
Certificats d'analyse (COA)
Lot/Batch Number
It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.
Si vous avez besoin d'assistance, veuillez contacter Service Clients
Déjà en possession de ce produit ?
Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.
ESA dose vs. Hb levels: what needs to be monitored?
Lynda Szczech
Nephrology news & issues, 27(7), Supp 4-Supp 5 (2013-07-17)
Anaemia in congestive heart failure.
T Eyre et al.
British journal of hospital medicine (London, England : 2005), 74(5), 252-257 (2013-05-10)
Why we can't trust clinical guidelines.
Jeanne Lenzer
BMJ (Clinical research ed.), 346, f3830-f3830 (2013-06-19)
Darbepoetin alfa in systolic heart failure.
Karl Swedberg et al.
The New England journal of medicine, 369(5), 488-489 (2013-08-02)
N A Makarova
Klinicheskaia meditsina, 91(1), 28-31 (2013-05-11)
AIM--to develop pathogenetic methods for the correction of dysregulated erythropoesis in coronary heart disease (CHD). 20 patients with myocardial Q-infarction and 52 ones with chronic CHD. 26 patients of the CHD group suffered anemia. Ten volunteers without signs of cardiovascular
Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..
Contacter notre Service technique